  Royal  DSM NV (Heerlen, the Netherlands, 

)  and Dutch biotechnology company Crucell NV (Leiden, the Netherlands, 

) have announced a  nonexclusive PER.C6 research licensing deal with Sartorius Biotech GmbH  (Goettingen, Germany, 

Sartorius  will use Crucell’s key technology to evaluate MAbs produced using PER.C6 cells  for calibrating and testing equipment products useful in the manufacture and  purification of recombinant MAbs. Crucell and Sartorius further agreed to  expand their PER.C6 collaboration by sharing technology and data on antibody  production. Financial details were not disclosed.

News

Royal DSM NV (Heerlen, the Netherlands, www.dsm.com) and Dutch biotechnology company Crucell NV (Leiden, the Netherlands, www.crucell.com) have announced a nonexclusive PER.C6 research licensing deal with Sartorius Biotech GmbH (Goettingen, Germany, www.sartorius.com).